190 related articles for article (PubMed ID: 31285177)
1. Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.
Dreher N; Hadeler EK; Hartman SJ; Wong EC; Acerbi I; Rugo HS; Majure MC; Chien AJ; Esserman LJ; Melisko ME
Clin Breast Cancer; 2019 Dec; 19(6):443-449.e1. PubMed ID: 31285177
[TBL] [Abstract][Full Text] [Related]
2. Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
Nyrop KA; Deal AM; Choi SK; Wagoner CW; Lee JT; Wood WA; Anders C; Carey LA; Dees EC; Jolly TA; Reeder-Hayes KE; Muss HB
Breast Cancer Res Treat; 2018 Feb; 168(1):43-55. PubMed ID: 29124455
[TBL] [Abstract][Full Text] [Related]
3. Use of Fitbit Devices in Physical Activity Intervention Studies Across the Life Course: Narrative Review.
St Fleur RG; St George SM; Leite R; Kobayashi M; Agosto Y; Jake-Schoffman DE
JMIR Mhealth Uhealth; 2021 May; 9(5):e23411. PubMed ID: 34047705
[TBL] [Abstract][Full Text] [Related]
4. Acceptability and feasibility of a Fitbit physical activity monitor for endometrial cancer survivors.
Rossi A; Frechette L; Miller D; Miller E; Friel C; Van Arsdale A; Lin J; Shankar V; Kuo DYS; Nevadunsky NS
Gynecol Oncol; 2018 Jun; 149(3):470-475. PubMed ID: 29692337
[TBL] [Abstract][Full Text] [Related]
5. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
6. Fitbit Use and Activity Levels From Intervention to 2 Years After: Secondary Analysis of a Randomized Controlled Trial.
Hartman SJ; Chen R; Tam RM; Narayan HK; Natarajan L; Liu L
JMIR Mhealth Uhealth; 2022 Jun; 10(6):e37086. PubMed ID: 35771607
[TBL] [Abstract][Full Text] [Related]
7. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
[TBL] [Abstract][Full Text] [Related]
8. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy.
Yang L; Zhong X; Pu T; Qiu Y; Ye F; Bu H
World J Surg Oncol; 2018 Mar; 16(1):51. PubMed ID: 29514654
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
[TBL] [Abstract][Full Text] [Related]
12. Wearable Use in an Observational Study Among Older Adults: Adherence, Feasibility, and Effects of Clinicodemographic Factors.
Paolillo EW; Lee SY; VandeBunte A; Djukic N; Fonseca C; Kramer JH; Casaletto KB
Front Digit Health; 2022; 4():884208. PubMed ID: 35754462
[TBL] [Abstract][Full Text] [Related]
13. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
14. Different subtypes of metaplastic breast cancer might have different sensitivity to neoadjuvant chemotherapy.
Altundag K
J BUON; 2019; 24(5):2205. PubMed ID: 31786895
[No Abstract] [Full Text] [Related]
15. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
17. Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
Yu KD; Wu SY; Liu GY; Wu J; Di GH; Hu Z; Hou YF; Chen CM; Fan L; Tang LC; Shen ZZ; Wu KJ; Zhuang ZG; Zhang HW; Shao ZM
Cancer; 2019 Jul; 125(13):2185-2193. PubMed ID: 30892700
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
[TBL] [Abstract][Full Text] [Related]
19. Impact of Breast Reconstruction on Time to Definitive Surgical Treatment, Adjuvant Therapy, and Breast Cancer Outcomes.
Jabo B; Lin AC; Aljehani MA; Ji L; Morgan JW; Selleck MJ; Kim HY; Lum SS
Ann Surg Oncol; 2018 Oct; 25(10):3096-3105. PubMed ID: 30014454
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]